Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
LB-P4 is developed by LISCure Biosciences in collaboration with Celltrion. The focus is on neurodegenerative diseases. Specifically, it targets Parkinson's and Alzheimer's.
LB-P4 is part of an oral microbiome drug pipeline. It uses bacteria-secreted exosomes. These can cross the blood-brain barrier. This is a major challenge in CNS disorder treatments.
LB-P4 is expected to start a Phase 1 trial.
Company information 2025-03-21
…